In a nutshell
This study looked at the safety and effectiveness of blinatumomab (Blincyto) in the treatment of unresponsive acute lymphoblastic leukemia (ALL). Researchers found that blinatumomab was safe and effective in the treatment of these patients.
Some background
Acute lymphoblastic leukemia is a type of cancer of the bone marrow. This can lead to abnormal cells of the immune system. Although more than 80% of patients enter remission after chemotherapy, some patients do not respond to standard therapies. Blinatumomab is a drug that allows the immune system to recognize and attack the cancer cells. It is important to research the safety and effectiveness of these medications, particularly in patients with unresponsive disease.
Methods & findings
49 patients with ALL that did not respond to previous treatment were included in the study. All patients were then treated with blinatumomab. They were followed-up for an average of 4.3 months.
22 (44.9%) patients had no signs of cancer after treatment. 16 of these patients later received a stem cell transplant. Patients survived without signs of cancer for an average of 7.5 months. The average overall survival time was 8.1 months. The most common side effect of treatment was infection. 4% of treated patients also had nerve damage.
The bottom line
The study concluded that blinatumomab was safe and effective in the treatment of unresponsive ALL.
The fine print
This study had a small sample size. Larger studies are needed to confirm results.
Published By :
Annals of Hematology
Date :
Sep 26, 2018
